MIRIS
23.9.2020 16:21:10 CEST | Business Wire | Press release
In March 2020, also Norway ran out of infection control equipment. In this critical phase, MIRIS, a top tier technology green real estate company, initiated a collaboration with China Development Integration Limited (CDIL), a major EPC integration corporation in the Silk Road initiative.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200923005669/en/
The two companies have a relationship with regards to building a large-scale smart city in Europe, and MIRIS realized the possibility of a cooperation with CDIL and its resources to ensure supply of high quality infection control equipment.
Together they fulfilled significant contracts regarding infection control equipment for several countries, including Norway.
In a market described as the "Wild West", this collaboration tells a different story. They controlled the entire value chain, and ensured deliveries without problems. Even a pandemic can create trust and cooperation that triggers new growth and development.
First of all, CDIL and MIRIS will further develop the infection control equipment collaboration under the ”Protect” brand – with the slogan; “Safe to buy – Safe to use”.
Secondly, they will ensure 12 months of high-volume deliveries of necessary equipment at high quality and competitive prices to Northern Europe.
Thirdly, they will ensure that as many people as possible have access to infection control equipment, and will distribute 10 million infection control masks free of charge to voluntary organizations. Many of these have been hit hard by the pandemic, and will be able to resell the masks to earn income in a demanding time, or distribute them free of charge to people for whom infection control equipment becomes too expensive.
Last but not the least, the companies will join forces to look at the possibilities of developing disposable infection control equipment that is degradable, so as to reduce the environmental impact.
The long-term goal of the two companies’ collaboration goes beyond infection control equipment: Sustainable healthy cities.
Building for a Sustainable Future
To create or reinvent a green city, the first step is to define the energy demand of this city. Energy saving and building optimization, can reduce the demand dramatically. The city will be digitized, and over 95 percent of the energy from the data centers will be reused as heat. With modern solar cell technology and energy saving, the city will become energy-positive: It will produce more energy than it consumes.
The necessary technology already exists. But it needs people who are able to put it together at competitive prices, and who have enough capital and ability to implement it. “CDIL and MIRIS are leading the way at a turning point. This cooperation mutually beneficial for both parties is the best way to solve the challenges of the future. MIRIS has the technology ready, and projects testing is underway,” says Mr. Lai, Chairman of CDIL.
CDIL will contribute capital, market access and other EPC resources to create green growth along the entire new Silk Road. A collaboration of two companies each with their respective distinctive resources will create huge gains for the community, and hopefully the whole world.
Jan Gunnar Mathisen, CEO, founder and majority owner of MIRIS, emphasizes the opportunities created for green finance.
“This signals the change of direction that is now underway. If in the future all countries stress green investments, everything will change”, says Mathisen.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200923005669/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kiabi Selects Navan to Centralise Global Travel Program11.5.2026 09:00:00 CEST | Press release
Fashion retailer targets high employee adoption and efficiency with AI-powered travel platform Navan (NASDAQ: NAVN), the global AI-powered business travel and expense platform, today announced it has been selected by Kiabi, the French multinational fashion retailer, to consolidate its global travel with one unified platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260511547434/en/ Fashion retailer targets high employee adoption and efficiency with AI-powered travel platform To support its workforce of nearly 10,000 “Kiabers,” the retailer required a solution capable of providing an easy-to-use travel platform. Navan was selected due to its intuitive AI-powered interface and ability to integrate with Kiabi’s travel policies directly in-app. “Managing travel was becoming an administrative burden that slowed our teams down,” said Denise Maurice, Indirect Procurement Director at Kiabi. “We wanted to give our ‘Kiabers’ the
Owl Labs partners with Westcoast to expand access to seamless hybrid meeting experiences in the UK and Ireland11.5.2026 09:00:00 CEST | Press release
Partnership aims to reduce the ‘meeting tax’ by expanding access to Owl Labs products through Westcoast’s extensive distribution network Owl Labs, a global leader in AI-powered, 360-degree video conferencing solutions, today announced a new UK and Ireland distribution partnership with Westcoast Limited, one of the country’s largest and most trusted IT distributors. The agreement will see Westcoast distribute the full range of Owl Labs’ award-winning Meeting Owl and Owl Bar products across the UK and Ireland, providing greater choice, availability, and dedicated support for resellers and end customers navigating the demands of hybrid work. The partnership aims to address the technical setup challenges that plague meetings across the UK. Owl Labs’ recent State of Hybrid Work report found that nearly 8 in 10 workers (79%) lose time in meetings due to technical difficulties such as connecting to a meeting or setting up a camera. By making Owl Labs’ solutions simpler to source, deploy and s
Fujirebio Announces CE Marking of the Fully Automated Lumipulse® G pTau 217 Plasma Assay11.5.2026 09:00:00 CEST | Press release
H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that Fujirebio Europe N.V. has obtained a CE certificate of the Lumipulse G pTau 217 Plasma assay under the Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR). This CLEIA (chemiluminescent enzyme immunoassay) test allows for the quantitative measurement of Tau phosphorylated at threonine 217 (pTau 217) in human plasma (K2EDTA). “With Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma now CE‑marked on our LUMIPULSE G platform, we are advancing a new era of neurology diagnostics—one where blood‑based biomarkers enable earlier, broader, and more accessible insights into Alzheimer’s disease and neurodegeneration.” said Christiaan De Wilde, CEO at Fujirebio Europe N.V. “By delivering fully automated and scalable solutions, we are helping clinicians move decisively toward more timely and informed decision‑making. This milestone underscores our long‑term vision to reimagine the diagnostic
Mevion Introduces the First Proton Therapy System Designed for a LINAC Vault at ESTRO 202611.5.2026 08:00:00 CEST | Press release
The MEVION S250-FIT™ creates a new pathway for European cancer centers to integrate proton therapy into existing radiotherapy programs Proton therapy is entering the LINAC vault. At ESTRO 2026, Mevion Medical Systems will introduce the MEVION S250-FIT Proton Therapy System to the European radiation oncology community, the first proton therapy system designed for installation in a standard radiation therapy vault. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507172087/en/ The MEVION S250-FIT™ Proton Therapy System Now both U.S. FDA-cleared and CE-marked under Regulation (EU) 2017/745, the S250-FIT creates a new pathway for cancer centers to bring proton therapy into existing LINAC-based treatment environments, aligning advanced proton capability with the infrastructure, workflows, and capital planning of modern radiation oncology. Stanford Medicine: First S250-FIT Installation On April 7, 2026, Stanford Medicine unveiled
Vedanta FY26 Profit Soars by 22% to $2.8 bn; Enters Demerger Phase11.5.2026 02:30:00 CEST | Press release
India-based Vedanta Limited (BSE: 500295 & NSE: VEDL), a global leader in metals, oil & gas, critical minerals, power and technology, announced its results for the fourth quarter and full year ended 31 March 2026. It has delivered its best-ever financial performance, driven by structurally strong businesses and disciplined execution. For the full year, Vedanta’s Profit stood at an all-time high of $2.8 bn, reflecting a 22% YoY increase and a profit of $1 bn in Q4 FY26, up nearly 90% YoY. Vedanta reported its highest-ever annual revenue of about $20 bn, up 15% YoY, with Q4 revenue at $5.6 bn, an increase of nearly 30% YoY. The Company maintained strong cost leadership, contributing to record EBITDA of $6.3 bn for FY26, up by about 30% YoY, with margins expanding to around 40%. Q4 EBITDA stood at $2.0 bn, up by nearly 60% YoY, with a margin of approximately 44%. The balance sheet strengthened further, with Net Debt/EBITDA improving to 0.95x, supported by strong cash generation. Underscor
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
